Axon Enterprise
AXON
$522.46
-14.28%
Axon Enterprise is a public safety technology company that designs and manufactures TASER energy devices, body cameras, and cloud-based digital evidence management software, operating at the intersection of hardware and software for law enforcement. As the dominant market leader in conducted energy weapons and body-worn cameras, Axon has built a sticky ecosystem that integrates devices with its Evidence.com platform, creating a recurring revenue model that sets it apart from traditional defense contractors. The current investor narrative centers on the company's explosive growth in AI-driven products and drone technology, which drove a strong Q1 2026 earnings beat and raised guidance, yet the stock remains down over 50% from its 52-week high, sparking debate about whether the market is mispricing its long-term potential or correctly discounting execution risks and valuation concerns.…
AXON
Axon Enterprise
$522.46
Related headlines
Investment Opinion: Should I buy AXON Today?
Based on the data, I rate AXON a Hold. The consensus 'Buy' rating and average target of $660.88 suggest upside, but the extreme valuation and profitability challenges temper enthusiasm. The thesis is that Axon's dominant market position and AI-driven growth justify a premium, but only if it can deliver on aggressive earnings expectations.
Sign up to view all
AXON 12-Month Price Forecast
The AI-driven growth narrative is compelling, but the extreme valuation and negative margins warrant caution. I would upgrade to a more bullish stance if operating margins turn positive and revenue growth sustains above 30%. Conversely, a downgrade would occur if growth decelerates below 20% or if the stock breaks below $400.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Axon Enterprise's 12-month outlook, with a consensus price target around $660.88 and implied upside of +26.5% versus the current price.
Average Target
$660.88
0 analysts
Implied Upside
+26.5%
vs. current price
Analyst Count
—
covering this stock
Price Range
$410 - $825
Analyst target range
Axon is covered by 19 analysts, with a consensus recommendation of 'Buy' and a mean recommendation score of 1.71 (where 1 is Strong Buy and 5 is Sell), indicating a strongly bullish stance. The average price target is $660.88, implying an upside of 25.2% from the current price of $527.76, while the high target of $825.00 suggests a potential 56.3% gain, and the low target of $409.68 implies a 22.4% downside. The wide spread between the low and high targets (over $415) reflects significant uncertainty about the company's future growth trajectory, with bulls betting on AI and drone adoption driving exponential revenue growth, while bears worry about valuation and competitive pressures.
Bulls vs Bears: AXON Investment Factors
Axon presents a classic growth-versus-valuation debate. The bull case rests on accelerating revenue growth (33.75% YoY), dominant market position, and strong analyst support (average target $660.88). The bear case hinges on an extreme trailing PE of 355x, negative operating margins, and a stock that has underperformed the market by 48 percentage points over the past year. Currently, the bearish evidence on valuation and profitability is more compelling, but the company's growth trajectory and AI-driven catalysts could quickly shift the balance. The single most important tension is whether Axon can translate its explosive revenue growth into sustainable profitability, which would justify its premium multiple.
Bullish
- Explosive Revenue Growth Accelerating: Q1 2026 revenue surged 33.75% YoY to $807.3M, accelerating from 18.4% growth in Q1 2025, driven by AI and drone demand. This momentum supports the bull case for sustained high growth.
- Dominant Market Position in Public Safety: Axon is the market leader in TASER devices and body cameras, with a sticky ecosystem integrating hardware and Evidence.com software. This creates high switching costs and recurring revenue, underpinning long-term growth.
- Strong Analyst Consensus and Upside: 19 analysts rate AXON a 'Buy' with a mean score of 1.71 (1=Strong Buy), and the average price target of $660.88 implies 25.2% upside from $527.76. High target of $825 suggests 56.3% potential gain.
- High Gross Margin and Recurring Revenue: Gross margin is robust at 59.7% (Q1 2026: 59.1%), reflecting a strong software mix. Software and Sensors revenue of $354.5M in Q1 2026 provides recurring, high-margin income.
Bearish
- Extreme Valuation with Trailing PE of 355x: At $527.76, AXON trades at 354.96x trailing earnings, implying the market expects massive future growth. Any disappointment could trigger severe multiple compression, as seen with the stock's 60% drawdown from highs.
- Stock Down 30% Over Past Year: AXON is down 30.14% over the trailing 12 months, while the S&P 500 gained 18.19%. This underperformance reflects persistent selling pressure and skepticism about valuation despite strong fundamentals.
- Negative Operating Margin and Cash Flow Concerns: Operating margin was -2.2% in Q1 2026, and free cash flow TTM is only $19.5M, indicating profitability challenges. Heavy R&D spending ($189M in Q1) pressures near-term earnings.
- High Beta and Market Sensitivity: With a beta of 1.378, AXON is more volatile than the market, amplifying downside in risk-off environments. The stock's 60.28% max drawdown highlights this risk.
AXON Technical Analysis
Axon's price trend over the past year has been decidedly bearish, with the stock down 30.14% over the trailing 12 months, a stark contrast to the S&P 500's 18.19% gain over the same period. The current price of $527.76 sits at approximately 59.6% of its 52-week range (between $339.01 low and $885.92 high), indicating the stock is closer to its lows than its highs, which typically suggests either a value opportunity or a falling knife depending on fundamental support. The 6-month price change of +9.14% shows some recovery from the April lows, but the stock remains well below its February peak, reflecting persistent selling pressure and a lack of conviction from buyers.
Beta
1.40
1.40x market volatility
Max Drawdown
-60.3%
Largest decline past year
52-Week Range
$339-$885
Price range past year
Annual Return
-39.5%
Cumulative gain past year
| Period | AXON Return | S&P 500 |
|---|---|---|
| 1m | -18.4% | +2.8% |
| 3m | +29.5% | +4.2% |
| 6m | +26.1% | +11.3% |
| 1y | -39.5% | +21.5% |
| ytd | -7.3% | +12.7% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
AXON Fundamental Analysis
Axon's revenue trajectory is robust, with Q1 2026 revenue of $807.3 million representing a 33.75% year-over-year growth rate, accelerating from the 18.4% growth seen in Q1 2025. The company's revenue has grown sequentially from $503.2 million in Q2 2024 to $807.3 million in Q1 2026, demonstrating a consistent upward trend, though the growth rate has fluctuated quarterly. The Connected Devices segment, which includes TASER and body cameras, remains the primary revenue driver, with TASER X2 alone generating $232.9 million, while Software and Sensors contributed $354.5 million, indicating a healthy mix of hardware and recurring software revenue.
Quarterly Revenue
$807345000.0B
2026-03
Revenue YoY Growth
+33.8%
YoY Comparison
Gross Margin
59.1%
Latest Quarter
Free Cash Flow
$19507000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is AXON Overvalued?
Given that Axon's trailing twelve-month net income is positive ($169.3 million in Q1 2026), the PE ratio is the most appropriate valuation metric, and at 354.96x trailing, it is astronomically high, reflecting the market's expectation of explosive future earnings growth. The forward PE of 50.18x implies a massive earnings expansion, as analysts project EPS to grow from $2.11 in Q1 2026 to $13.78 on average, a 553% increase, which seems overly optimistic given the company's historical profitability. The PEG ratio of -5.23 is negative due to negative earnings growth expectations in the near term, further complicating the valuation picture.
PE
355.0x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 32x~170x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
236.1x
Enterprise Value Multiple
Investment Risk Disclosure
Financial risks are significant. Axon's trailing PE of 355x leaves no room for error; any earnings miss could trigger a sharp de-rating. The company's operating margin was -2.2% in Q1 2026, and free cash flow TTM is a mere $19.5M, indicating that growth is consuming capital. Debt-to-equity of 0.59 is manageable, but the negative operating margin and reliance on continued investment in R&D ($189M in Q1) pose risks to near-term profitability. Revenue concentration in the Connected Devices segment (TASER and cameras) exposes the company to product-specific demand shocks.